Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00132522
Status:
COMPLETED
Last Update Posted:
2013-10-25
First Post:
2005-08-19
Brief Title:
EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian Prostate Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide
Sponsor:
EMD Serono
Organization:
EMD Serono
Study Overview
Official Title:
A Study to Find the Highest Dose of Biological Study Drug EMD 273066 That Can Be Given Safely to Patients With Recurrent EpCAM Positive Ovarian Prostate Colorectal or Non-Small Cell Lung Cancers When First Given a Low Dose of Cyclophosphamide
Status:
COMPLETED
Status Verified Date:
2013-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is looking at the safety and tolerability of the experimental biological drug EMD 273066 when given with low dose cyclophosphamide to patients with recurring EpCAM positive ovarian prostate colorectal or non-small cell lung cancers EMD 273066 is an experimental biological drug that may increase the immune response to certain cancers Patients will be enrolled in groups of 3 with each successive group receiving a higher dose if the prior group adequately tolerates the study medication
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None